Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage

Study Overview
=================
Brief Summary
-----------------
To delineate the effect of MSM on osteoarthritis

Detailed Description
-----------------
Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design: Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups. Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured are the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and SF-36 (overall health-related quality of life).

Official Title
-----------------
The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: MethylSulfonylMethane (MSM)
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Knee and hip OA men and women >45 years of age Exclusion Criteria: any other type of arthritis chronic pain syndrome arthroscopic surgery in the past 8 months intra-articular corticosteroidsin the past 8 months hyaluronic acid injections in the past 8 months narcotic pain killers use renal or hepatic disease body mass index (BMI) >45 kg/m2 cancer

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MSM group<br>Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total) | Drug: MethylSulfonylMethane (MSM)<br>* Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)<br>|
| Placebo Comparator: Placebo Group<br>Placebo 3 gr twice a day for 26 weeks (6 gr/day total) | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with improved Mobility | Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA were divided in 2 groups. Intervention was either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured were the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC) | 26 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Scores on the Visual Analog Scale | On the same two groups (MSM and Placebo)we measured the improvement of quality of life through pain relief as measured by use of SF-36 (overall health-related quality of life) | 26 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
osteoarthritis, CAM treatments, MSM